Acetaminophen or Fluvastatin Compared to Placebo on the Transient Post-Dose Symptoms (PDS) Following an Intravenous (i.v.) Infusion of a Single Dose of Zoledronic Acid 5mg, in Post-Menopausal Women With Low Bone Mass

Condition(s) targeted: Low Bone Mass

Intervention: Zoledronic Acid (Drug); Acetaminophen and Fluvastatin (Drug); Placebo (Drug)

Phase: Phase 4

Status: Completed

Sponsored by: Novartis

This study will evaluate the efficacy of acetaminophen or fluvastatin in reducing the rate of occurrence and the severity of post dose symptoms that may occur during the 3 day period following a zoledronic acid infusion in post menopausal women with low bone mass.

Official title: A Randomized, Multicenter, Double-Blind, Double-Dummy, Parallel-Group Study of Acetaminophen or Fluvastatin Compared to Placebo on the Transient Post-Dose Symptoms (PDS) Following an i.v. Infusion of a Single Dose of Zoledronic Acid 5mg, in Post-Menopausal Women With Low Bone Mass

Study design: Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Placebo Control, Parallel Assignment, Safety/Efficacy Study

Primary outcome: Change in oral body temperature from baseline to 3 days following zoledronic acid infusion in patients receiving acetaminophen vs. placebo

Secondary outcome:

Change in oral body temperature from baseline to 3 days following zoledronic acid infusion in patients receiving fluvastatin vs. placebo

Severity of patient reported outcomes (feeling feverish, experiencing headaches, having aches and pains of muscles and joints) in patients receiving acetaminophen vs. placebo and fluvastin vs. placebo.

Proportion of patients reporting severe questionnaire-solicited symptoms (feeling feverish, experiencing headaches, having aches and pains of muscles and joints) in patients receiving acetaminophen vs. placebo and fluvastin vs. placebo

Effect on severity of symptoms using a 100mm Visual Analog Scale measured at baseline and daily over a 3 day period following infusion (comparing Acetaminophen to placebo and Fluvastatin to placebo)

Evaluate the time to rescue medication , proportion of patients taking rescue medication, and quantity of rescue medication , over a 3 day period following Zoledronic Acid Infusion (comparing Acetaminophen to placebo and Fluvastatin to placebo)

Minimum age: 45 Years. Maximum age: 79 Years. Gender(s): Female.

Criteria:

Inclusion Criteria:

1. Postmenopausal women greater than or equal to 45 and less than or equal to 79 years of age at randomization

2. Women who are clinically indicated for treatment with Bisphosphonates for osteopenia or osteoporosis with a documented central (spine or hip) Bone Mineral Density T Score less than or equal to 1. 5

Exclusion Criteria:

1. Any prior treatment with intravenous Bisphosphonates

2. Oral treatment with Bisphosphonates for more than 8 weeks or within 6 months prior to the screening visit

3. Patients who are taking, and are unwilling or unable to stop taking, certain medications

4. Patients who require anticoagulant therapy

5. Patients with a known hypersensitivity to ibuprofen, ACET, bisphosphonates, statins or with allergies manifested by attacks of asthma, urticaria or acute rhinitis following

6. Proteinuria (protein detected on a urine dipstick) greater than or equal to 2+ at screening

7. Protocol specific laboratory values that fall out of range for this study

8. Ongoing infection (oral body temperature greater than or equal to 37. 5C (99. 5°F),chronic febrile disease or fever of unknown origin at screening or randomization

9. Active dental infection, unhealed dental extraction or planned oral surgery within 3 months after randomization

10. History of iritis, uveitis or chronic conjunctivitis

11. History of hypoparathyroidism, hyperparathyroidism or Paget's Disease

12. Partial or total removal of parathyroid or thyroid gland

13. History of malignancy of any organ system, treated or untreated, within the past 1 year whether or not there is evidence of local recurrence or metastases, with the exception of localized basal cell carcinoma of the skin

14. Treatment with an investigational drug within the previous 30 days of screening

15. Patients with any medical or psychiatric condition which, in the opinion of the Principal Investigator, would preclude the participant from adhering to the protocol or completing the trial per protocol, or any patient who the Principal Investigator thinks should not participate in the study for any reason, including current drug or alcohol abuse

Other protocol-defined inclusion/exclusion criteria may apply

Refer to the E-portal link for ZOL446HUS136, http://www.osteoporosisclinicalresearch.com, New Jersey, United States

Click here for more information on this study

Starting date: June 2007
Ending date: December 2007
Last updated: December 19, 2007